Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Tokyo University of Science Foundation has 8 pending office actions in Biotechnology & Pharmaceuticals. The docket involves 8 examiners across 7 art units, showing broad examiner dispersion with limited overlap among technical groups.
QIAN, SHIZHI is the busiest examiner, with 1 pending matter. No examiner accounts for a recurring share of the docket, so counsel should coordinate scientific claim themes while adapting responses to each examination assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, SHIZHI | 1 | 62.0% | +46.2% |
| CUMAR, NATHAN | 1 | 78.8% | +14.6% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| WAHEED, NAZRA NUR | 1 | 84.7% | +10.6% |
| SWEELY, KURT D | 1 | 52.5% | +34.2% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | — |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | — |
| 18708827 | ANTI-SARS-COV-2 DRUG | WARD, PAUL V | — |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | — |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | — |
| 18566013 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | LAU, JONATHAN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | — |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | — |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | — |
| 18703525 | LIQUID CIRCULATION SYSTEM, SUBSTRATE PROCESSING APPARATUS, AND LIQUID CIRCULATION METHOD | SWEELY, KURT D | — |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | — |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | NGUYEN, NGHI V | — |
| Art Unit | Apps |
|---|---|
| 1795 | 1 |
| 3675 | 1 |
| 1622 | 1 |
| 2844 | 1 |
| 1647 | 1 |
| 1693 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | 1795 | §103§112 | Non-Final OA | — | Pending | Feb 24, 2025 |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | 3675 | §102§103 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18708827 | ANTI-SARS-COV-2 DRUG | WARD, PAUL V | 1622 | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | 2844 | §103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18703525 | LIQUID CIRCULATION SYSTEM, SUBSTRATE PROCESSING APPARATUS, AND LIQUID CIRCULATION METHOD | SWEELY, KURT D | — | §103 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | 1647 | §101§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18566013 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | LAU, JONATHAN S | 1693 | §103§112 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTokyo University of Science Foundation has 8 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Shizhi Qian has the most, with 1 of Tokyo University of Science Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
